CN102215859B - 垂体腺苷酸环化酶激活多肽（pacap）以及pacap类似物作为与抗癌剂一起的辅助治疗的用途 - Google Patents

垂体腺苷酸环化酶激活多肽（pacap）以及pacap类似物作为与抗癌剂一起的辅助治疗的用途 Download PDF

Info

Publication number
CN102215859B
CN102215859B CN200980145368.4A CN200980145368A CN102215859B CN 102215859 B CN102215859 B CN 102215859B CN 200980145368 A CN200980145368 A CN 200980145368A CN 102215859 B CN102215859 B CN 102215859B
Authority
CN
China
Prior art keywords
pacap38
pacap
apply
analog
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980145368.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102215859A (zh
Inventor
李敏
杰罗姆·L·马德德勒特
戴维·H·科伊
韦基·巴图曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tulane University
Original Assignee
Tulane University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tulane University filed Critical Tulane University
Publication of CN102215859A publication Critical patent/CN102215859A/zh
Application granted granted Critical
Publication of CN102215859B publication Critical patent/CN102215859B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CN200980145368.4A 2008-09-25 2009-09-25 垂体腺苷酸环化酶激活多肽（pacap）以及pacap类似物作为与抗癌剂一起的辅助治疗的用途 Expired - Fee Related CN102215859B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19416608P 2008-09-25 2008-09-25
US61/194,166 2008-09-25
PCT/US2009/058445 WO2010036936A2 (en) 2008-09-25 2009-09-25 Use of pituitary adenylate cyclase-activating polypeptide (pacap) and pacap analogs as adjunctive treatments with anticancer agents

Publications (2)

Publication Number Publication Date
CN102215859A CN102215859A (zh) 2011-10-12
CN102215859B true CN102215859B (zh) 2016-04-20

Family

ID=42060409

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980145368.4A Expired - Fee Related CN102215859B (zh) 2008-09-25 2009-09-25 垂体腺苷酸环化酶激活多肽（pacap）以及pacap类似物作为与抗癌剂一起的辅助治疗的用途

Country Status (7)

Country Link
US (1) US20110268789A1 (enExample)
EP (1) EP2337577A4 (enExample)
JP (1) JP2012503674A (enExample)
CN (1) CN102215859B (enExample)
AU (1) AU2009296456B2 (enExample)
CA (1) CA2738549A1 (enExample)
WO (1) WO2010036936A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5908406B2 (ja) 2009-11-02 2016-04-26 ジ アドミニストレーターズ オブ ザ トゥレーン エデュケーショナル ファンド 下垂体アデニル酸シクラーゼ活性化ポリペプチド（ｐａｃａｐ）の類似体およびその使用方法
CA2788835A1 (en) * 2010-02-05 2011-08-11 The Administrators Of The Tulane Educational Fund The use of pituitary adenylate cyclase-activating polypeptide (pacap) and pacap analogs as adjunctive treatments with inhibitors of calcineurin or inhibitors of the mammalian target of rapamycin (mtor) complexes
US9353171B2 (en) * 2011-11-17 2016-05-31 The Administrators Of The Tulane Educational Fund Use of pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP analogs for treating contrast-induced nephropathy
CN103145851B (zh) * 2013-02-22 2014-07-02 暨南大学 重组蛋白PACAP38-NtA及其编码基因与应用
WO2018129200A2 (en) 2017-01-05 2018-07-12 The Regents Of The University Of California Pac1 receptor agonists (maxcaps) and uses thereof
ES2677242B1 (es) * 2017-01-31 2019-03-27 Univ Alcala Henares Nanoconjugados formados por moléculas dendríticas y péptidos como agentes antitumorales frente al cáncer
JP7695772B2 (ja) * 2017-11-14 2025-06-19 千寿製薬株式会社 Ｐａｃａｐの安定化ペプチド
JPWO2020230869A1 (enExample) * 2019-05-14 2020-11-19
DE102024001175A1 (de) * 2024-04-04 2025-10-09 ReViSan Healthcare GmbH Zubereitung zur Behandlung von entzündlichen Erkrankungen der Atemwege.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1993137A (zh) * 2004-06-11 2007-07-04 维克特斯生物系统有限公司 用于治疗心血管疾病的组合物和方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003092716A2 (en) * 2002-05-03 2003-11-13 Neuronova Ab Therapeutic use of pacap, maxadilan, pacap receptor agonist and/or adcyap1r1 in the treatment of cns disorders
US9006181B2 (en) * 2004-07-21 2015-04-14 The Administrators Of The Tulane Educational Fund Treatment of renal dysfunction and multiple myeloma using PACAP compounds
AU2008303956A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Proadrenomedullin alone or in combination with big gastrin I as a therapeutic agent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1993137A (zh) * 2004-06-11 2007-07-04 维克特斯生物系统有限公司 用于治疗心血管疾病的组合物和方法

Also Published As

Publication number Publication date
AU2009296456A1 (en) 2010-04-01
WO2010036936A9 (en) 2010-07-15
EP2337577A1 (en) 2011-06-29
WO2010036936A2 (en) 2010-04-01
CN102215859A (zh) 2011-10-12
JP2012503674A (ja) 2012-02-09
US20110268789A1 (en) 2011-11-03
EP2337577A4 (en) 2012-08-15
AU2009296456B2 (en) 2016-06-16
CA2738549A1 (en) 2010-04-01

Similar Documents

Publication Publication Date Title
CN102215859B (zh) 垂体腺苷酸环化酶激活多肽（pacap）以及pacap类似物作为与抗癌剂一起的辅助治疗的用途
JP5908406B2 (ja) 下垂体アデニル酸シクラーゼ活性化ポリペプチド（ｐａｃａｐ）の類似体およびその使用方法
US20160122406A1 (en) Analogs of pituitary adenylate cyclase-activating polypeptide (pacap) and methods for their use
US20120309683A1 (en) USE OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGS AS ADJUNCTIVE TREATMENTS WITH INHIBITORS OF CALCINEURIN OR INHIBITORS OF THE MAMMALIAN TARGET OF RAPAMYCIN (mTOR) COMPLEXES
CN113476589A (zh) 肽在制造用于治疗神经退行性疾病的组合物中的用途
CN107001419A (zh) 神经变性障碍
EP3197482A1 (en) Methods of treating traumatic brain injury
KR20220145888A (ko) 선택적 gip 수용체 작용제로서의 펩티드
US20200261541A1 (en) Methods of treating mild brain injury
WO2017075535A1 (en) Methods of treating neurodegenerative conditions
EP1778268B1 (en) Treatment of renal dysfunction and multiple myeloma using pacap compounds
KR20220051418A (ko) 근위축성 측삭 경화증 치료제
JPWO2017170926A1 (ja) 神経保護ペプチド

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160420

Termination date: 20180925

CF01 Termination of patent right due to non-payment of annual fee